Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 14/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 14/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987403 | 1.00 | ITGB1 (0.38) | ITGB1ITGA4SLC10A1ITGB3ITGA2B | |
| SCHEMBL2986901 | 0.90 | ITGB1 (0.41) | ITGB1ITGA4SLC10A1ITGB3ITGA2B | |
| SCHEMBL2981066 | 0.85 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL5147702 | 0.84 | ITGB1 (0.34) | ITGB1ITGA4SLC10A1ICAM1SELE | |
| SCHEMBL5262264 | 0.79 | ITGB1 (0.38) | ITGB1ITGA4 | |
| SCHEMBL5260326 | 0.79 | ITGB1 (0.38) | ITGB1ITGA4 | |
| SCHEMBL2978545 | 0.79 | ITGB1 (0.43) | ITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL2978548 | 0.79 | ITGB1 (0.43) | ITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL2982408 | 0.78 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL5149334 | 0.78 | JAK2 (0.38) | ITGB1ITGA4ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | ITGB1 77/4885ITGA4 462/4885SLC10A1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.